Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat, in phase ...

Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of its in-vivo candidate, CTX310, as well as better-than-expected sales of ...

Equine Healthcare Global equine healthcare market expands with rising horse ownership, equestrian sports, and demand for preventive care, t ...

LONDON, GREATER LONDON, UNITED KINGDOM, August 19, 2025 /EINPresswire.com/ -- Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry ...

Tenaya Therapeutics advances gene therapies, TN-201 and TN-401, for heart disorders. Key data in Q4 2025 could drive value.